stock report Archives

Thanks for a Bull Market | Cabot Weekly Review

From the issue of | |

In this week's video (recorded on Wednesday morning), Paul Goodwin, chief analyst of Cabot Global Stocks Explorer (formerly Cabot Emerging Markets Investor), looks at the general state of the market and sees plenty to be thankful for. The major indexes are in uptrends and worries,...
Read More

Celgene (CELG)

From the issue of |

This biotech is growing at double-digit rates, just settled a major patent litigation suit, and 16 of its 19 analysts rate the stock a ‘buy’ or ‘strong buy’. Celgene (CELG) From Wong’s BioTech Stock Report Celgene’s (CELG) core business has three franchises, hematologic malignancy, solid and...
Read More

Silver Wheaton Corp. (SLW)

From the issue of |

This ETF recently rose above its 50-day Moving Average, a possible bullish indicator. Four analysts have increased their earnings forecasts for the ETF in the past 30 days. Silver Wheaton Corp. (SLW) From Gold & Silver Stock Report In light of the immediate-term bottoming attempt the...
Read More

Let’s Do Lunch!

From the issue of |

In the middle of October, I hosted a webinar called Lunch with the Analyst. It was an informal affair, featuring me sitting in front of a Mac in Cabot’s conference room talking about stocks. In just 60 minutes, I gave a rundown on was...
Read More

Incyte (INCY)

From the issue of |

Rising sales backed by a recent FDA approval are boosting this Top Pick biotech’s shares. Incyte (INCY) from Wong’s BioTech Stock Report Incyte’s (INCY) Jakafi was launched in myelofibrosis (MF), as a treatment for a rare bone marrow cancer during 2011. Third quarter 2014 sales were 63%...
Read More

iStar Financial, Inc. (SFI)

From the issue of |

Real estate investment trusts (REITs) normally show up in our other publication, Dick Davis Dividend Digest. But today we have a REIT for growth and value investors. As Coolcat Explosive Small Cap Growth Stock Report Editor Kevin Kennedy notes below, this REIT had suspend...
Read More